Evaluation of the fibrinolytic potential on plasma: Physiological and pathological variations, and associations with cardio-vascular disease risk factors

Fibrinolysis and Proteolysis

Volumn 13, Issue SUPPL. 1, 1999, Pages 1-10

  Amiral, J ^a,g   Malmejac, A ^b   Gin, H ^c   Pannell, R ^d   Vissac, A M ^e   Seigneur, M ^f   Scarabin, P Y ^a   Boisseau, M ^e   Guize, L ^c   Gurewich, V ^a  

^a IPC Center   (France)

^b CHU Groupe Sud   (France)

^c New England Diaconess Hospital   (United States)

^d Serbio   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f HÔPITAL BROUSSAIS   (France)

^g SYSMEX CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ALPHA 2 ANTIPLASMIN; APROTININ; BINDING PROTEIN; BLOOD CLOTTING FACTOR 12; CITRIC ACID; D DIMER; GLUCOSE; GLYCOPROTEIN; HISTIDINE; LYSINE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROUROKINASE; SILICON DIOXIDE; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; UROKINASE;

AGE; BIOASSAY; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CHEMICAL REACTION KINETICS; CONFERENCE PAPER; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PLASMA; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033036408     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Juhan-Vague l, Alessi MC. Fibrinolysis and risk of coronary artery disease. Fibrinolysis 1996; 10: 127-136.
2. Amiral J, Plassart V, Grosley M, Mimilla F, Contant G, Guyader AM. Measurement of t-PA and t-PA-PAI-1 complexes by ELISA, using monoclonal antibodies : clinical relevance. Thromb Res 1988: Sup VIII: 99-113.
3. Gurewich V, Emmons F, Pannell R. Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasm inogen activators : demonstration of a promoting effect by t-PA and by platelets on urokinase. Fibrinolysis 1988; 2: 143-149.
4. Chakrabarti R, Fearnley GR. The fibrinolytic potential as a simple measure of spontaneous fibrinolysis. J Clin Path 1962; 15:228-230
5. Von Kaula K.N, Von Kaula E. Remarks on the euglobulin lysis time. Prog Chem Fibrin Thromb 1975; 1: 131-149.
6. Nsiri B, Gritli N, Mazigh C, Gazhouani E, Fattoum S, Maghghoul S. Fibrinolytic response to venous occlusion in patients with homozygous sickle cell disease. Hemato CellTher 1997; 39: 229-232.
7. Anglés-Cano E. A spectrophotometric solid-phase fibrintissue plasminogen activator activity assay (SOFIA-t-PA) for high-fibrin-affinity tissue plasminogen activators. Anal Biochem 1986; 153: 201-210.
8. Holvoet P. Boes J, Collew D. Measurement of free, one chain tissue-type plasminogen activator in human plasma with an enzyme-linked immuno sorbent assay based on an active-site specific murine monoclonal antibody. Blood 1987; 69: 284-289.
9. Amiral J, Plassart V. Contant G. Guyader AM. Different methods for the determination of tissue plasminogen activator (t-PA) and of its inhibitor (PAI). J Clin Lab Inst Reag 1990; 13: 599-610.
10. Ridker PM. Intrinsic fibrinolytic capacity and systemic inflammation : novel risk factors for arterial thrombotic disease. Haemostasis 1997:27: 2-11.
11. Smith FB, Lee AJ, Rumley A, Fowkes FOR, Löwe GDO. Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease. Atherosclerosis 1995; 115: 35-43.
12. Meade TW. Ruddock V, Stirling Y, Chakrabarty R, Miller GJ. Fibrinolytic activity, clotting factors, and longterme incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 10761079.
13. Catto AJ, Grant PJ. Risk factors for cerebrovascular disease and the role of coagulation and fibrinolysis. Blood Coag Fibrinolysis 1995; 6: 497-510.
14. Sloan IG. Firkin BG. Impaired fibrinolysis in patients with thrombotic or haemostatic defects. Thromb Res 1989; 55: 559-567.
15. Fujii S. PAI-I in thrombosis and arteriosclerosis. Fibrinol Proteol 1997; 11: 137-140.
16. Robbie LA. Bennett B. Croll AM. Brown PAJ. Booth NA. Proteins of the fibrinolytic system in human thrombi. Thromb Haemostasis 1996:75: 127-133.
17. Robbie LA. Booth N A. Brown PAJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Atherioscl Thromb Vase Biol 1996; 16: 539-545.
18. Chesebro JH, Rauch U, Fuster V, Badimon JJ. Pathogenesis of thrombosis in coronary artery disease. Haemostasis 1997; 27: 12-18.
19. Musial J, Pajak A, Undas A et al. Thrombin generation markers and coronary heart disease risk factors in a Polish population sample. Thromb Haemostasis 1997; 77: 697-700.
20. Smith FB, Rumley A. Lee AJ, Leng GC, Fowkes FOR, Löwe GDO. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998; 100:758-763.25.
21. Uchiyama S, Yamazaki M, Hara Y, Iwata M. Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischémie stroke. Semin Thromb Hemost 1997; 23: 535-541.
22. Mellbring G, Dahlgren S, Wiman B. Sunnegardh O. Relationship between preoperative status of the fibrinolytic system and occurrence of deep vein thrombosis after major abdominal surgery. Thromb Res 1985;39: 157-163.
23. Jorgensen M. Bonnevie-Nielsen V. Increased concentration of the fast acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br J Haemat 1987; 65: 175-180.
24. Declerck PJ, Juhan-Vague 1, Felez J, Wiman B. Minisymposium : The role of the fibrinolytic system in the pathophysiology and treatment of thrombosis. Pathophysiology of fibrinolysis. J Int Med 1994; 236: 425-432.
25. Kazal LA, Amsel S. Miller OP, Tocantins LM. The preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc Soc Exp Biol Med 1963; 1 13: 989-994.
26. Kapiotis S, Jilma B , Quehenberger P, Ruzicka K, Handler S, Speiser W. Morning hypercoagulability and hypofibrinolysis : diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin inhibitor complex. Circulation 1997; 96: 19-21.
27. Pannell R, Black J, Gurewich V. The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained. J Clin Invest 1988; 81:853-859.
28. Kluft C, Jie AFH. Route of activation, in vitro, of the factor XII dependent pathway of fibrinolysis. Fibrinolysis 1994:8: 172-176.
29. Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis: study in healthy subjects and correlation with blood fibrinolytic parameters. Thromb Haemostasis 1997; 77: 725-729.
30. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J Biol Chem 1996; 271: 16603-606.
31. Vissac AM, Scarabin PY, Malmejac A et al. Association of cardio-vascular risk factors with a deficient fibrinolysis in healthy population (Thrombocheck study). Fibrinolysis 1996; 10: 103.
32. Amiral J, Seigneur M, Vissac AM, Boisseau M, Scarabin PY, Gin H. Highly impaired fibrinolysis in non-insulindependent but not in insulin-dependent diabetes (Thrombocheck study). Fibrinolysis 1996; 10: 87.
33. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vase Biol 1997; 17: 3071-3078.
34. Stegnar M. Ambrozic J, Berger B, Keber I. In vitro plasma and euglobulin clot lysis in subjects with elevated lipoprotein (a). Fibrinolysis 1995; 9: 304-308.
35. Tremoli E, Sironi L, Camera M. et al. Triglycérides and the fibrinolytic system. Med Sei Symp Ser 1995; 8: 379-384.
36. Daae LNW, Kierulf P, Landaas S, Urdal P. Cardiovascular risk factors: interactive effects of lipids, coagulation and fibrinolysis. Scand J Clin Lab Invest 1993; 53: 19-27.
37. Duane WC. Cholesterol metabolism in familial hypertriglyceridemia; effects of obesity versus triglycéride level. J Eab Clin Med 1997; 130: 635-642.
38. Martina V, Bruno GA, Trucco F et al. Platelet cNOS activity is reduced in patients with IDDM and NIDDM. Thromb Haemostasis 1998; 79; 520-522.
39. Hughes K, Aw TC, Kuperan P, Choo M. Central obesity, insulin resistance, syndrome X, lipoprotein (a), and cardiovascular risk in Indians, Malays, and Chinese in Singapore. J Epidemiol Commun Health 1997. 51: 394-399.
40. Lamon-Fava S, Wilson PWF, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women. Arterioscl Thromb Vase Biol 1996; 16: 1509-1515.
41. Lindahl B, Asplund K, Eliasson M, Evrin PE. Insulin resistance syndrome and fibrinolytic activity: the Northern Sweden Monica study. Int J Epidemiol 1996; 25:291-299.
42. Tkac I, Kimball BP, Lewis G, Uffelman K, Steiner G. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscl Thromb Vase Biol 1997; 17: 3633-3638.
43. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993; 270: 2207-2212.
44. Peternel P, Stegnar M, Mavri A, Salobir-Pajnic B. The effect of fasting and/or body weight reduction on tissuetype plasminogen activator (t-PA) and plasminogen activator inhibitor (PA1-1). Fibrinolysis 1994; 8 (Supp 2): 41-43.
45. Juhan-Vague I, Alessi MC, Badier C et al. Relationships between plasma insulin, triglycéride, body mass index and plasminogen activator I. Diab Metabol 1987; 13: 331-336.